Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

详细信息    查看全文

• 作者：Hanna Vasarainen ; Jolanda Salman ; Heidi Salminen…
• 关键词：Prostate cancer ; Active surveillance ; Prostate ; specific antigen ; Free prostate ; specific antigen
• 刊名：World Journal of Urology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：33
• 期：11
• 页码：1735-1740
• 全文大小：460 KB
• 参考文献：1.Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2):S14–S19PubMedCentral CrossRef PubMed
  2.Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5(2):101–106CrossRef PubMed
  3.Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603CrossRef PubMed
  4.Dall’Era MA, Konety BR, Cowan JE et al (2008) Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112(12):2664–2670CrossRef PubMed
  5.van As NJ, Norman AR, Thomas K et al (2008) Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54(6):1297–1305CrossRef PubMed
  6.Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131CrossRef PubMed
  7.Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16):2185–2190CrossRef PubMed
  8.Ouzzane A, Puech P, Villers A (2012) MRI and surveillance. Curr Opin Urol 22(3):231–236CrossRef PubMed
  9.Stamatakis L, Siddiqui MM, Nix JW et al (2013) Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119(18):3359–3366CrossRef PubMed
  10.Isharwal S, Makarov DV, Sokoll LJ et al (2011) ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 77(3):763.e1–763.e6CrossRef
  11.Catalona WJ, Smith DS, Wolfert RL et al (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274(15):1214–1220CrossRef PubMed
  12.Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48(6A Suppl):55–61CrossRef PubMed
  13.Visapaa H, Hotakainen K, Lundin J, Ala-Opas M, Stenman UH (2010) The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy. Urol Int 84(4):378–381CrossRef PubMed
  14.Ramirez ML, Nelson EC, Deverewhite RW, Lara PN Jr, Evans CP (2008) Current applications for prostate-specific antigen doubling time. Eur Urol 54(2):291–300CrossRef PubMed
  15.van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52(6):1560–1563CrossRef PubMed
  16.Southwick PC, Catalona WJ, Partin AW et al (1999) Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351CrossRef PubMed
  17.Catalona WJ, Southwick PC, Slawin KM et al (2000) Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56(2):255–260CrossRef PubMed
  18.Nam RK, Toi A, Klotz LH et al (2007) Assessing individual risk for prostate cancer. J Clin Oncol 25(24):3582–3588CrossRef PubMed
  19.Selvadurai ED, Singhera M, Thomas K et al (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64(6):981–987CrossRef PubMed
  20.San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC (2011) Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 185(2):471–476CrossRef PubMed
  21.Kotb AF, Tanguay S, Luz MA, Kassouf W, Aprikian AG (2011) Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 14(1):53–57PubMedCentral CrossRef PubMed
  22.Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS (2013) Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int 111(3):396–403CrossRef PubMed
  23.Ng MK, Van As N, Thomas K et al (2009) Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity versus PSA doubling time. BJU Int 103(7):872–876CrossRef PubMed
  24.Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB (2013) Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol 191(3):629–637
  25.Vellekoop A, Loeb S, Folkvaljon Y, Stattin P (2014) Population based study of predictors of adverse pathology among candidates for active surveillance with gleason 6 prostate cancer. J Urol 191(2):350–357CrossRef PubMed
  26.Steuber T, Vickers AJ, Serio AM et al (2007) Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53(2):233–240CrossRef PubMed
  27.Southwick PC, Catalona WJ, Partin AW et al (1999) Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351CrossRef PubMed
  28.Elabbady AA, Khedr MM (2006) Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3–10 ng/ml. Int Urol Nephrol 38(3–4):553–557PubMed
  
• 作者单位：Hanna Vasarainen (1)
  Jolanda Salman (2)
  Heidi Salminen (1)
  Riccardo Valdagni (3)
  Tom Pickles (4)
  Chris Bangma (2)
  Monique J. Roobol (2)
  Antti Rannikko (1)
  
  1. Department of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland
  2. Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
  3. Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  4. Department of Radiation Oncology and Developmental Radiotherapeutics, University of British Columbia, and BC Cancer Agency, Vancouver, Canada
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  Nephrology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-8726

文摘

Purpose To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial.